Alternative pathways of NF-κB activation: A double-edged sword in health and disease

Cytokine and Growth Factor Reviews

Volumn 17, Issue 4, 2006, Pages 281-293

  Xiao, Gutian ^a   Rabson, Arnold B ^b,c   Young, Wise ^a   Qing, Guoliang ^a   Qu, Zhaoxia ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Autoimmune disease; Cancer; NF B; Protein processing; Therapeutic target

Indexed keywords

I KAPPA B KINASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P52; TAX PROTEIN;

AUTOIMMUNE DISEASE; CANCER; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOREGULATION; IMMUNOSTIMULATION; LEUKEMIA; LYMPHOMA; MOLECULAR DYNAMICS; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; UPREGULATION;

AUTOIMMUNE DISEASES; HUMANS; NEOPLASMS; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; SIGNAL TRANSDUCTION;

EID: 33745852665     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2006.04.005     Document Type: Review

References (113)

1. Ghosh S., May M.J., and Kopp E.B. NF-κB and rel protein: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 (1998) 225-260
2. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18 (2000) 621-623
3. Silverman N., and Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev 15 (2001) 2321-2342
4. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 (2002) S81-S96
5. Rayet B., and Gelinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
6. Baldwin Jr. A.S. Series introduction: the transcription factor of NF-κB and human disease. J Clin Invest 107 (2001) 3-6
7. Sun S.C., and Xiao G. Deregulation of NF-κB and its upstream kinases in cancer. Cancer Metastasis Rev 22 (2003) 405-422
8. Wulczyn F.G., Naumann M., and Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB. Nature 358 6387 (1992) 597-599
9. Zhang Q., Didonato J.A., Karin M., and McKeithan T.W. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins. Mol Cell Biol 14 6 (1994) 3915-3926
10. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., et al. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 72 5 (1993) 729-739
11. Fujita T., Nolan G.P., Liou H.C., Scott M.L., and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev 7 7B (1993) 1354-1363
12. Yamamoto M., Yamazaki S., Uematsu S., Sato S., Hemmi H., Hoshino K., et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ. Nature 430 6996 (2004) 218-222
13. Rice N.R., MacKichan M.L., and Israel A. The precursor of NF-κB p50 has IκB-like functions. Cell 71 (1992) 243-253
14. Mercurio F., DiDonato J.A., Rosette C., and Karin M. p105 and p98 precursor proteins play an active role in NF-κB-mediated signal transduction. Genes Dev 7 (1993) 705-718
15. Xiao G., Harhaj E.W., and Sun S.C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 7 (2001) 401-409
16. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 (1999) 6853-6866
17. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., and Karin. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388 6642 (1997) 548-554
18. Regnier C.H., Song H.Y., Gao X., Goeddel D.V., Cao Z., and Rothe M. Identification and characterization of an IκB kinase. Cell 90 2 (1997) 373-383
19. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278 5339 (1997) 860-866
20. Chen G., Cao P., and Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9 2 (2002) 401-410
21. Sigala J.L., Bottero V., Young D.B., Shevchenko A., Mercurio F., and Verma I.M. Activation of transcription factor NF-κB requires ELKS, an IκB kinase regulatory subunit. Science 304 5679 (2004) 1963-1967
22. Broemer M., Krappmann D., and Scheidereit C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 23 31 (2004) 5378-5386
23. May M.J., D'Acquisto F., Madge L.A., Glockner J., Pober J.S., and Ghosh S. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289 5484 (2000) 1550-1554
24. Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., et al. Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα. EMBO J 20 23 (2001) 6805-6815
25. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., and Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115 5 (2003) 565-576
26. Yamamoto Y., Verma U.N., Prajapati S., Kwak Y.T., and Gaynor R.B. Histone H3 phosphorylation by IKKα is critical for cytokine-induced gene expression. Nature 423 6940 (2003) 655-659
27. Anest V., Hanson J.L., Cogswell P.C., Steinbrecher K.A., Strahl B.D., and Baldwin A.S. A nucleosomal function for IκB kinase α in NF-κB-dependent gene expression. Nature 423 6940 (2003) 659-663
28. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107 6 (2001) 763-775
29. Matta H., and Chaudhary P.M. Activation of alternative NF-κB pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1β-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 101 25 (2004) 9399-9404
30. Hu Y., Baud V., Oga T., Kim K.I., Yoshida K., and Karin M. IKKα controls formation of the epidermis independently of NF-κB. Nature 410 6829 (2001) 710-714
31. Lawrence T., Bebien M., Liu G.Y., Nizet V., and Karin M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434 7037 (2005) 1138-1143
32. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., et al. Activation by IKKα of a second, evolutionary conserved NF-κB signaling pathway. Science 293 5534 (2001) 1495-1499
33. Xiao G., Fong A., and Sun S.C. Induction of p100 Processing by NF-κB-inducing kinase involves docking IκB kinase α (IKK α) to p100 and IKK α-mediated phosphorylation. J Biol Chem 279 29 (2004) 30099-30105
34. Schmidt C., Peng B., Li Z., Sclabas G.M., Fujioka S., Niu J., et al. Mechanisms of proinflammatory cytokine-induced biphasic NF-κB activation. Mol Cell 12 5 (2003) 1287-1300
35. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat Genet 27 3 (2001) 277-285
36. Jain A., Ma C.A., Liu S., Brown M., Cohen J., and Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2 3 (2001) 223-228
37. Huang T.T., Feinberg S.L., Suryanarayanan S., and Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-κB activation by UV radiation and topoisomerase inhibitors. Mol Cell Biol 22 16 (2002) 5813-5825
38. Xiao G., Harhaj E.W., and Sun S.C. Domain-specific interaction with the IκB kinase (IKK) regulatory subunit IKKγ is an essential step in Tax-mediated activation of IKK. J Biol Chem 275 44 (2000) 34060-34067
39. Tang E.D., Wang C.Y., Xiong Y., and Guan K.L. A role for NF-κB essential modifier/IκB kinase-γ (NEMO/IKKγ) ubiquitination in the activation of the IκB kinase complex by tumor necrosis factor-α. J Biol Chem 278 39 (2003) 37297-37305
40. Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., et al. Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 427 6970 (2004) 167-171
41. Sun L., Deng L., Ea C.K., Xia Z.P., and Chen Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14 3 (2004) 289-301
42. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12 6 (2003) 1413-1426
43. Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B., Mueller-Dieckmann C., et al. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α. Cell 86 5 (1996) 787-798
44. Bender K., Gottlicher M., Whiteside S., Rahmsdorf H.J., and Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-κB by UV. EMBO J 17 17 (1998) 5170-5181
45. Li N., and Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci USA 95 22 (1998) 13012-13017
46. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 412 6847 (2001) 641-647
47. Sosic D., Richardson J.A., Yu K., Ornitz D.M., and Olson E.N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-κB activity. Cell 112 2 (2003) 169-180
48. Greene W.C., and Chen L.F. Regulation of NF-κB action by reversible acetylation. Novartis Found Symp 259 (2004) 208-217
49. Delhase M., Hayakawa M., Chen Y., and Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284 5412 (1999) 309-313
50. Chen Z.J. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 7 8 (2005) 758-765
51. Wang Y., Tang Y., Teng L., Wu Y., Zhao X., and Pei G. Association of β-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 7 2 (2006) 139-147
52. Heyninck K., and Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci 30 1 (2005) 1-4
53. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., and Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424 6950 (2003) 793-796
54. Brummelkamp T.R., Nijman S.M., Dirac A.M., and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424 6950 (2003) 797-801
55. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., and Courtois G. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424 6950 (2003) 801-805
56. Jono H., Lim J.H., Chen L.F., Xu H., Trompouki E., Pan Z.K., et al. NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: Evidence for a novel inducible auto-regulatory feedback pathway. J Biol Chem 279 35 (2004) 36171-36174
57. Li Q., Lu Q., Bottero V., Estepa G., Morrison L., Mercurio F., et al. NF-κB activation and cellular function in macrophages lacking IκB kinase 1 (IKK1). Proc Natl Acad Sci USA 102 35 (2005) 12425-12430
58. Franzoso G., Carlson L., Poljak L., Shores E.W., Epstein S., Leonardi A., et al. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 187 2 (1998) 147-159
59. Caamano J.H., Rizzo C.A., Durham S.K., Barton D.S., Raventos-Suarez C., Snapper C.M., et al. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 187 2 (1998) 185-196
60. Ishikawa H., Carrasco D., Claudio E., Ryseck R.P., and Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med 186 7 (1997) 999-1014
61. Ishikawa H., Claudio E., Dambach D., Raventos-Suarez C., Ryan C., and Bravo R. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-κB1) but expressing p50. J Exp Med 187 7 (1998) 985-996
62. Fracchiolla N.S., Lombardi L., Salina M., Migliazza A., Baldini L., Berti E., et al. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene 8 10 (1993) 2839-2845
63. Thakur S., Lin H.C., Tseng W.T., Kumar S., Bravo R., Foss F., et al. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 9 8 (1994) 2335-2344
64. Zhang J., Chang C.C., Lombardi L., and Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9 7 (1994) 1931-1937
65. Fong A., and Sun S.C. Genetic evidence for the essential role of β-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem 277 25 (2002) 22111-22114
66. Solan N.J., Miyoshi H., Carmona E.M., Bren G.D., and Paya C.V. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 277 2 (2002) 1405-1418
67. Li X., Commane M., Burns C., Vithalani K., Cao Z., and Stark G.R. Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol 19 7 (1999) 4643-4652
68. Bonnet M.C., Weil R., Dam E., Hovanessian A.G., and Meurs E.F. PKR stimulates NF-κB irrespective of its kinase function by interacting with the IκB kinase complex. Mol Cell Biol 20 13 (2000) 4532-4542
69. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., and Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12 4 (2000) 419-429
70. Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 3 10 (2002) 958-965
71. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 17 4 (2002) 515-524
72. Coope H.J., Atkinson P.G., Huhse B., Belich M., Janzen J., Holman M.J., et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J 21 (2002) 5375-5385
73. Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., and Yamaoka S. TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J Biol Chem 278 38 (2003) 36005-36012
74. Novack D.V., Yin L., Hagen-Stapleton A., Schreiber R.D., Goeddel D.V., Ross F.P., et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198 5 (2003) 771-781
75. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 17 (2002) 525-535
76. Qing G., Qu Z., and Xiao G. Stabilization of basally translated NF-κB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100. J Biol Chem 280 49 (2005) 40578-40582
77. Bradley J.R., and Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20 (2001) 6482-6491
78. Malinin N.L., Boldin M.P., Kovalenko A.V., and Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF CD95 and IL-1. Nature 38 (1997) 540-544
79. Song H., Regnier C., Kirschning C., Goeddel D., and Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94 (1997) 9792-9796
80. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., and Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 21 5 (2004) 629-642
81. Liao G., Zhang M., Harhaj E.W., and Sun S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279 25 (2004) 26243-26250
82. Qu Z., Qing G., Rabson R., and Xiao G. Tax deregulation of NF-κB2 p100 processing involves both β-TrCP-dependent and independent mechanisms. J Biol Chem 279 43 (2004) 44563-44572
83. Qing G., Qu Z., Qing G., and Xiao G. Regulation of NF-κB2 p100 processing by its cis-activating domain. J Biol Chem 280 1 (2005) 18-27
84. Liao G., and Sun S.C. Regulation of NF-κB2/p100 processing by its nuclear shuttling. Oncogene 22 31 (2003) 4868-4874
85. Xiao G., and Sun S.C. Negative regulation of the nuclear factor kappa B-inducing kinase by a cis-acting domain. J Biol Chem 275 28 (2000) 21081-21085 [Erratum in: J Biol Chem 2001;276(9):6880]
86. Hu W.H., Mo X.M., Walters W.M., Brambilla R., and Bethea J.R. TNAP a novel repressor of NF-κB-inducing kinase, suppresses NF-κB activation. J Biol Chem 279 34 (2004) 35975-35983
87. Ardila-Osorio H., Pioche-Durieu C., Puvion-Dutilleul F., Clausse B., Wiels J., Miller W., et al. TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int J Cancer 113 2 (2005) 267-275
88. Miyawaki S., Nakamura Y., Suzuka H., Koba M., Yasumizu R., Ikehara S., et al. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur J Immunol 24 2 (1994) 429-434
89. Shinkura R., Kitada K., Matsuda F., Tashiro K., Ikuta K., Suzuki M., et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase. Nat Genet 22 1 (1999) 74-77
90. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 5537 (2001) 2108-2111
91. Sha W.C., Liou H.C., Tuomanen E.I., and Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80 2 (1995) 321-330
92. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 11 (1999) 1697-1710
93. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., et al. B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97 7 (2000) 3370-3375
94. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15 2 (2001) 289-302
95. Ciana P., Neri A., Cappellini C., Cavallo F., Pomati M., Chang C.C., et al. Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene 14 (1997) 1805-1810
96. Qing G., and Xiao G. Essential role of IκB kinase α in the constitutive processing of NF-κB2 p100. J Biol Chem 280 11 (2005) 9765-9768
97. Jeang K.T. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-κB. Cytokine Growth Factor Rev 12 2-3 (2001) 207-217
98. Xiao G., and Sun S.C. Activation of IKKα and IKKβ through their fusion with HTLV-I Tax protein. Oncogene 19 45 (2000) 5198-5203
99. Moore P.S., and Chang Y. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?. Annu Rev Microbiol 57 (2003) 609-639
100. Liu L., Eby M.T., Rathore N., Sinha S.K., Kumar A., and Chaudhary P.M. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the IκB kinase complex. J Biol Chem 277 16 (2002) 13745-13751
101. Lam N., and Sugden B. CD40 and its viral mimic LMP1: similar means to different ends. Cell Signal 15 1 (2003) 9-16
102. Saito N., Courtois G., Chiba A., Yamamoto N., Nitta T., Hironaka N., et al. Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-κB through distinct signaling pathways in fibroblast cell lines. J Biol Chem 278 47 (2003) 46565-46575
103. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 19 9 (2000) 1123-1131
104. Chandler N.M., Canete J.J., and Callery M.P. Increased expression of NF-κB subunits in human pancreatic cancer cells. J Surg Res 118 1 (2004) 9-14
105. Park H.R., Min S.K., Cho H.D., Kim D.H., Shin H.S., and Park Y.E. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J Korean Med Sci 18 4 (2003) 541-546
106. Tong A.W., and Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10 1 (2003) 1-13
107. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 4 (2002) 301-310
108. Dhawan P., and Richmond A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277 10 (2002) 7920-7928
109. Mackay F., and Tangye S.G. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4 4 (2004) 347-354
110. Rolink A.G., and Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr Opin Immunol 14 2 (2002) 266-275
111. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 62 Suppl. 2 (2003) ii25-ii27
112. Zarnegar B., He J.Q., Oganesyan G., Hoffmann A., Baltimore D., and Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. Proc Natl Acad Sci USA 101 21 (2004) 8108-8113
113. Datta S.K., and Kalled S.L. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 40 10 (1997) 1735-1745